Braveheart Bio, Inc.
BRVE
$27.03
$1.064.08%
NASDAQ
| 03/31/2026 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 4.14M | 5.00K | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 15.05M | 99.00K | |||
| Operating Income | -15.05M | -99.00K | |||
| Income Before Tax | -14.28M | -99.00K | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -14.28M | -99.00K | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -14.28M | -99.00K | |||
| EBIT | -15.05M | -99.00K | |||
| EBITDA | -15.05M | -- | |||
| EPS Basic | -0.48 | -- | |||
| Normalized Basic EPS | -0.30 | -- | |||
| EPS Diluted | -0.48 | -- | |||
| Normalized Diluted EPS | -0.30 | -- | |||
| Average Basic Shares Outstanding | 30.06M | -- | |||
| Average Diluted Shares Outstanding | 30.06M | -- | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||